

State of Oklahoma SoonerCare

Tibsovo® (Ivosidenib) Prior Authorization Form

wember name:	Date of Birth:	Member ID#:	
	Drug Informatio	n	
Pharmacy Billing (NDC:) Start Date (c	or date of next dose):	
Dose:	Regimen:		
	Billing Provider Infor	mation	
Pharmacy NPI:	Pharmacy Na	Pharmacy Name: Pharmacy Fax: Prescriber Information	
Pharmacy Phone:	Pharmacy Fa	x:	
	Prescriber Informa	ation	
Prescriber NPI:	Prescriber Name:		
Prescriber Phone:	Prescriber Fax:	Specialty:	
	Criteria		
YesNo ii. Has an IDH1 r iii.Will Tibsovo® B. Is AML relapsed or i. Will Tibsovo® ii. Has an IDH1 r Cholangiocarcinoma A. Is diagnosis locally B. Has an IDH1 muta C. Has the member re If answer is none of t	nosed? Yes No have comorbidities that preclude mutation been detected? Yes (ivosidenib) be used as a single- r refractory? Yes No (ivosidenib) be used as a single- mutation been detected? Yes y advanced or metastatic cholang tion been detected? Yes No eceived prior treatment for this desired.	agent? Yes No agent? Yes No _ No giocarcinoma? Yes No o iagnosis? Yes No Inosis:	
For Continued Authorization 1. Date of last dose: 2. Does member have any ev 3. Has the member experience If yes, please specify adverse	ridence of progressive disease weed adverse drug reactions relate	hile on ivosidenib? Yes No ed to ivosidenib therapy? Yes No	

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 157 7/28/2022